Arcus Biosciences In Collaboration With Gilead Sciences, Completes Patient Enrollment In Phase 3 Trial Evaluating A Domvanalimab-Containing Regimen In First-Line Metastatic Upper GI Cancers
Author: Benzinga Newsdesk | June 10, 2024 08:38am
- Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the completion of patient enrollment for STAR-221, a Phase 3 study in collaboration with Gilead Sciences, evaluating the combination of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.
Posted In: GILD RCUS
